Cannabis Industry Financial Reporting: GAAP Compliance Challenges

April 22, 2026

By: Paul Lembo

Partner, Assurance

Key Takeaways

Cannabis businesses operate under GAAP requirements identical to every other industry, but apply them to operational structures, inventory flows, and cost allocation scenarios that most accountants have never encountered.
The most consequential GAAP challenges in cannabis are inventory valuation and cost allocation. Misapplying these directly affects taxable income, investor reporting, and audit outcomes simultaneously.
Seed-to-sale tracking requirements create unusually detailed cost data that, when properly structured, supports defensible GAAP financials. When not structured, it creates a compliance liability.
Vertically integrated cannabis operators face compounding complexity. Cost decisions made at the cultivation stage cascade through processing and retail, affecting gross margin at every level.
Bottom line: Cannabis financial reporting is not a niche problem. It is a standard GAAP problem applied to a genuinely unusual operating structure, and it requires accountants who understand both.

Most industries that struggle with GAAP compliance do so because the accounting standards are new or ambiguous. Cannabis struggles for a different reason: the accounting standards are clear, but applying them to the day-to-day realities of a cannabis operation requires judgment that the FASB never specifically contemplated and that most CPAs have never had to exercise.

The gap between what GAAP requires and how most cannabis businesses actually maintain their books is where auditors find adjustments, where investors lose confidence, and where IRS auditors focus their scrutiny. Closing that gap requires understanding exactly where cannabis financial reporting diverges from standard practice.

Inventory Valuation: Where Most Cannabis Financial Statements Break Down

Under ASC 330, inventory must be carried at the lower of cost or net realizable value. That rule applies to cannabis the same way it applies to any manufacturer. The challenge is determining cost accurately in an operating environment where cost flows are genuinely complex.

A cannabis cultivation operation produces raw flower, which serves as the input for multiple downstream products. Some of that biomass becomes retail flower. Some becomes concentrate. Some become the input for infused products. Each of these follows a different cost pathway to the balance sheet. If those pathways are not structured correctly in the accounting system, costs are averaged or lumped, and the resulting inventory values are incorrect.

The consequences extend beyond the balance sheet. Incorrect inventory values flow directly into cost of goods sold, affecting gross margin reporting and what investors see and what auditors verify. For operators seeking growth capital or preparing for an institutional investment round, inventory accounting that cannot be audited to a defensible cost methodology is a deal-killer.

Under GAAP, inventory costs for a cannabis cultivator include direct materials, direct labor, and allocated overhead. What that overhead allocation looks like and how it is tracked through the production process are where operators most frequently fall short. Grow facility overhead, drying and curing costs, and trimming labor all belong in inventory under GAAP. Treating them as period expenses instead is not conservative accounting. It is a GAAP error.

The COGS Methodology Problem That Follows Cannabis Businesses Into Audits

Section 471 of the Internal Revenue Code governs the capitalization of costs into inventory for tax purposes, and cannabis businesses have historically received intense IRS scrutiny on their COGS calculations precisely because 280E made COGS the only deductible cost category available. Auditors and the IRS both know that cannabis businesses have every incentive to maximize COGS, and they review it accordingly.

The Tax Court established in a line of cases culminating in Patients Mutual Assistance Collective Corp. (Harborside) v. Commissioner, 151 T.C. No. 11 (2018), that the structure of a cannabis business’s activities matters enormously for expense treatment. The Court consistently applied 280E broadly, denying deductions to businesses in which cannabis-adjacent activities could not be shown to constitute genuinely separate trades or businesses. The foundational case, CHAMP v. Commissioner, 128 T.C. 173 (2007), established the framework: true separation of activities required separate employees, separate facilities, and separate economic rationale, not just separate accounting entries.

Post-rescheduling, the 280E restriction is expected to be lifted for Schedule III operators. But scrutiny of the COGS methodology will not. Auditors and investors will still want to see cost allocation that is methodologically defensible, consistently applied, and documented through contemporaneous records rather than reconstructed at year-end.

Cannabis businesses that built rigorous COGS documentation practices under 280E are better positioned for what comes next. Those who did not will find the transition period more painful than expected.

Biological Asset Accounting for Cultivators

Cultivation operators face a GAAP question that is genuinely unusual: how to account for plants in the ground. Cannabis plants in active growth are biological assets, and while U.S. GAAP does not have a specific standard for agricultural biological assets the way International Financial Reporting Standards do under IAS 41, ASC 330 still governs how cultivation costs are accumulated and when they transfer to inventory.

The practical issue is determining the capitalization point. Costs incurred during cultivation accumulate as work-in-process inventory. When the plant is harvested, those accumulated costs transfer to finished goods or raw material inventory, depending on how the operator uses the biomass. If cultivation costs are not properly tracked and accumulated throughout the growth cycle, the inventory value at harvest is either understated or unsupported.

Smaller operators often expense cultivation costs as incurred rather than capitalizing them through the production process. This produces an income statement that appears worse than it should and understates inventory on the balance sheet. For operators being valued on EBITDA multiples or carrying inventory as collateral for a business loan, this error has direct cash consequences.

Revenue Recognition Across the Cannabis Supply Chain

Revenue recognition under ASC 606 requires recognizing revenue when performance obligations are satisfied. For a retail dispensary, that is straightforward: revenue is recognized at the point of sale to the customer. For a vertically integrated operator selling wholesale to dispensaries, or a multi-state operator with intercompany transfer pricing, it is considerably more nuanced.

Intercompany transactions between related entities must be eliminated in consolidated financial statements. Transfer prices between a cultivation subsidiary and a retail subsidiary affect gross margin presentation at each entity level, even when they net to zero at consolidation. Operators who have not established formal intercompany pricing policies and documentation find themselves explaining these figures to auditors who are already skeptical.

Cash-intensive operations also create challenges for revenue recognition documentation. Point-of-sale systems that do not integrate with the general ledger, daily cash reconciliations handled manually, and tip-handling practices that vary by location all create conditions in which revenue can be misstated without deliberate intent. The internal controls required to ensure completeness and accuracy of revenue reporting in a cash-intensive cannabis operation are more demanding than those of most other retail businesses.

Why Standard Accounting Firms Struggle With Cannabis Financial Reporting

The GAAP challenges in cannabis are not exotic. They are inventory valuation, cost allocation, revenue recognition, and consolidation, which are the core disciplines of any manufacturing and retail accounting practice. The difficulty is that applying them to a cannabis operation requires specific knowledge of seed-to-sale tracking systems, state-specific compliance requirements, the interplay between COGS methodology and tax exposure, and the operational realities of cash-intensive multi-state businesses.

Accountants who lack that operational familiarity make conservative choices that are technically defensible but financially suboptimal, or they miss the cannabis-specific nuances that turn GAAP errors into audit findings. Neither outcome serves the business owner.

The Financial Infrastructure Your Cannabis Business Actually Needs

Wiss works with cannabis businesses to build financial reporting systems that meet GAAP requirements, withstand regulatory scrutiny, and produce the auditable financial statements that institutional investors and lenders expect. The cannabis industry is moving toward the financial infrastructure that legitimacy requires. The businesses that build that infrastructure now will be better positioned for the growth opportunities ahead.

If your current financial reporting does not align with the operational sophistication of your cannabis business, contact Wiss to discuss how our advisory services can close the gap.